200 related articles for article (PubMed ID: 15844007)
1. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
Ebi H; Sigeoka Y; Saeki T; Kawada K; Igarashi T; Usubuchi N; Ueda R; Sasaki Y; Minami H
Cancer Chemother Pharmacol; 2005 Aug; 56(2):205-11. PubMed ID: 15844007
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
Minami H; Ebi H
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2053-7. PubMed ID: 16352928
[TBL] [Abstract][Full Text] [Related]
3. Relationship between AUC of 5'-DFUR and toxicity of capecitabine, fluoropyrimidine carbamate analogs, and 5'-DFUR in monkeys, mice, and rats.
Shindoh H; Kawashima A; Shishido N; Nakano K; Kobayashi K; Horii I
J Toxicol Sci; 2006 Aug; 31(3):265-85. PubMed ID: 16960436
[TBL] [Abstract][Full Text] [Related]
4. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
[TBL] [Abstract][Full Text] [Related]
5. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
Reigner B; Watanabe T; Schüller J; Lucraft H; Sasaki Y; Bridgewater J; Saeki T; McAleer J; Kuranami M; Poole C; Kimura M; Monkhouse J; Yorulmaz C; Weidekamm E; Grange S
Cancer Chemother Pharmacol; 2003 Sep; 52(3):193-201. PubMed ID: 12783206
[TBL] [Abstract][Full Text] [Related]
7. Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
Czejka M; Schueller J; Farkouh A; Gruenberger B; Scheithauer W
Cancer Chemother Pharmacol; 2011 Mar; 67(3):613-9. PubMed ID: 20495919
[TBL] [Abstract][Full Text] [Related]
8. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug.
Mata JF; García-Manteiga JM; Lostao MP; Fernández-Veledo S; Guillén-Gómez E; Larrayoz IM; Lloberas J; Casado FJ; Pastor-Anglada M
Mol Pharmacol; 2001 Jun; 59(6):1542-8. PubMed ID: 11353816
[TBL] [Abstract][Full Text] [Related]
9. Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer.
Mader RM; Schrolnberger C; Rizovski B; Brunner M; Wenzel C; Locker G; Eichler HG; Mueller M; Steger GG
Br J Cancer; 2003 Mar; 88(5):782-7. PubMed ID: 12618890
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.
Di Desidero T; Orlandi P; Fioravanti A; Cremolini C; Loupakis F; Marmorino F; Antoniotti C; Masi G; Lonardi S; Bergamo F; Zagonel V; Falcone A; Bocci G
Invest New Drugs; 2018 Aug; 36(4):709-714. PubMed ID: 29488048
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
[TBL] [Abstract][Full Text] [Related]
12. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
Ait-Tihyaty M; Rachid Z; Mihalcioiu C; Jean-Claude BJ
Breast Cancer Res Treat; 2012 May; 133(1):217-26. PubMed ID: 21915635
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological and clinical properties of Xeloda (Capecitabine), a new oral active derivative of fluoropyrimidine].
Nishida M
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):549-53. PubMed ID: 14639009
[TBL] [Abstract][Full Text] [Related]
16. Preferential inhibition of bone metastases by 5'-deoxy-5-fluorouridine and capecitabine in the 4T1/luc mouse breast cancer model.
Hiraga T; Hata K; Ikeda F; Kitagaki J; Fujimoto-Ouchi K; Tanaka Y; Yoneda T
Oncol Rep; 2005 Sep; 14(3):695-9. PubMed ID: 16077977
[TBL] [Abstract][Full Text] [Related]
17. ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
Magné N; Fischel JL; Dubreuil A; Formento P; Ciccolini J; Formento JL; Tiffon C; Renée N; Marchetti S; Etienne MC; Milano G
Clin Cancer Res; 2003 Oct; 9(13):4735-42. PubMed ID: 14581344
[TBL] [Abstract][Full Text] [Related]
18. Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030).
Louie SG; Ely B; Lenz HJ; Albain KS; Gotay C; Coleman D; Raghavan D; Shields AF; Gold PJ; Blanke CD
Br J Cancer; 2013 Oct; 109(7):1744-9. PubMed ID: 24022189
[TBL] [Abstract][Full Text] [Related]
19. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.
Nishimura G; Terada I; Kobayashi T; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Kayahara M; Shimizu K; Ohta T; Miwa K
Oncol Rep; 2002; 9(3):479-82. PubMed ID: 11956613
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Mackean M; Planting A; Twelves C; Schellens J; Allman D; Osterwalder B; Reigner B; Griffin T; Kaye S; Verweij J
J Clin Oncol; 1998 Sep; 16(9):2977-85. PubMed ID: 9738566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
